Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $43.40.

Several brokerages have recently issued reports on ELVN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Mizuho boosted their price objective on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a report on Wednesday, March 25th. Finally, HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th.

Insider Activity

In other news, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. The trade was a 16.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Richard A. Heyman sold 1,230 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the transaction, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. The trade was a 5.15% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 37,460 shares of company stock valued at $1,041,104 over the last three months. Insiders own 25.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after purchasing an additional 913 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Swiss National Bank increased its holdings in Enliven Therapeutics by 1.7% during the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after buying an additional 1,100 shares during the last quarter. Finally, Quantbot Technologies LP increased its holdings in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Stock Performance

Shares of NASDAQ ELVN opened at $48.11 on Friday. The firm’s 50 day moving average price is $33.16 and its 200-day moving average price is $25.38. The company has a market cap of $2.93 billion, a PE ratio of -25.87 and a beta of 0.26. Enliven Therapeutics has a 52-week low of $14.78 and a 52-week high of $48.53.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.06). On average, analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.